IO Biotech

OverviewSuggest Edit

IO Biotech is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines, which suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

TypePrivate
Founded2014
HQKøbenhavn, DK
Websiteiobiotech.com

Latest Updates

Cybersecurity ratingAMore

Key People/Management at IO Biotech

Peter Hirth

Peter Hirth

Chairman
Mai-Britt Zocca

Mai-Britt Zocca

Chief Executive Officer and Founder
Emmanuelle Coutanceau

Emmanuelle Coutanceau

Director
Christian Elling

Christian Elling

Director
Claus Andersson

Claus Andersson

Director
Ayako Wakatsuki Pedersen

Ayako Wakatsuki Pedersen

VP, Translational Research
Show more

IO Biotech Office Locations

IO Biotech has an office in København
København, DK (HQ)
3 Ole Maaløes Vej
Show all (1)

IO Biotech Financials and Metrics

Summary Metrics

Founding Date

2014

IO Biotech total Funding

$165.9 m

IO Biotech latest funding size

$153.88 m

Time since last funding

8 months ago

IO Biotech investors

IO Biotech's latest funding round in January 2021 was reported to be $153.9 m. In total, IO Biotech has raised $165.9 m
Show all financial metrics

IO Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

IO Biotech Online and Social Media Presence

Embed Graph

IO Biotech News and Updates

IO Biotech Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

COPENHAGEN, Denmark, July 8, 2021 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today the appointment of Keith Vendola, M.D., M.B.A., as chief financial...

Novo Seeds' Portfolio Company, IO Biotech, Completes Oversubscribed EUR 127M Series B Financing to Accelerate Clinical Programs in Oncology

COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ -- Novo Seeds, the early-stage investment and company creation team of Novo Holdings, announced today that its portfolio company, IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer...

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing. The...

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

COPENHAGEN, Denmark, Feb. 25, 2020 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing...

IO Biotech participará en la mesa redonda de la 30.ª Conferencia anual sobre la evolución del cáncer en Nueva York

COPENHAGUE, Dinamarca, 2 de mayo de 2019 /PRNewswire/ -- La consejera delegada de IO Biotech, la Dra. Mai-Britt Zocca, participará en una mesa redonda titulada "IO Session I: Combination Failures & Futures: Much Ado About What?"(Sesión I de IO: combinación de fracasos y futuros: ¿mucho...

IO Biotech Presents Data on an Immunomodulatory CCL22-based Vaccine at the American Association for Cancer Research Annual Meeting 2019

COPENHAGEN, Denmark, April 1, 2019 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, presented preclinical data on the therapeutic potential of an immunomodulatory...
Show more

IO Biotech Blogs

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma

Copenhagen, Denmark – December 15, 2020:  IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma. IO102 …

IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent

- Data to be Presented at the ESMO Virtual Congress 2020 - Melanoma trial (MM1636) shows best-in-class efficacy data in first line melanoma of IO102 and IO103 in combination with nivolumab (anti-PD1 antibody) Copenhagen, Denmark – September 18, 2020: IO Biotech, a clinical-stage biopharmaceutical co…

IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win® Immunotherapy in Non-small Cell Lung Cancer

Copenhagen, Denmark – May 15, 2019: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the initiation of the Phase 2 portion of a global, open-label, randomized clinical trial studying…

IO Biotech to Participate in Panel Discussion at 30th Annual Cancer Progress Conference in New York

Copenhagen, Denmark – April 30, 2019:  IO Biotech’s CEO, Mai-Britt Zocca, Ph.D., will participate in a panel discussion entitled, “IO Session I: Combination Failures & Futures: Much Ado About What?” at the 30th Annual Cancer Progress Conference in New York City on May 7-8, 2019.  IO Biotech will…

New publication: Durable clinical responses in stage III–IV non-small-cell lung cancer patients treated with IDO peptide vaccine in a phase I study

Copenhagen, Denmark – September 28, 2018:  IO Biotech has published a brief research report describing long term follow-up of phase I study in stage III-IV NSCLC in "Frontiers in Immunology"

IO Biotech Frequently Asked Questions

  • When was IO Biotech founded?

    IO Biotech was founded in 2014.

  • Who are IO Biotech key executives?

    IO Biotech's key executives are Peter Hirth, Mai-Britt Zocca and Emmanuelle Coutanceau.

  • Who are IO Biotech competitors?

    Competitors of IO Biotech include XBiotech, Confo Therapeutics and Rubius Therapeutics.

  • Where is IO Biotech headquarters?

    IO Biotech headquarters is located at 3 Ole Maaløes Vej, København.

  • Where are IO Biotech offices?

    IO Biotech has an office in København.

  • How many offices does IO Biotech have?

    IO Biotech has 1 office.